Adam Bonislawski

Called optiPRM, the approach could help detect cancer neoantigens in patient tumor samples for applications like the development of personalized cancer vaccines.

A pair of Nature Medicine studies show how researchers are using the UKB's latest proteomic data release, which covers roughly 3,000 proteins in 54,000 subjects.

Researchers including Northwestern's Neil Kelleher and UVA's Gloria Sheynkman are exploring whether the platform could complement their mass spec analyses.

The rule could force labs to shed tests deemed nonessential to their institutions' missions as well as influence decisions around instrumentation and vendor choices.

In the first six months of 2024, deal volume was up 7 percent versus the same period in 2023 while total investment was up more than 50 percent.

Observers suggested that recent and ongoing shifts in the legal landscape may put the FDA in a less advantageous position than it might have enjoyed in the past.

Developed by Cedars-Sinai researchers, the workflow uses immunoenrichment combined with acoustic ejection mass spec for high-throughput protein measurements.

More advanced instrumentation and a shift to label-free approaches have boosted depth of coverage but led to fewer cells analyzed and at a higher cost per cell.

Olink's platform appears to have better specificity, but many researchers suggest such comparisons are less useful than better understanding both tools' capabilities.

Bruker and Waters launched updates of flagship instruments, while Thermo Fisher released what some users see as a step forward for targeted quantitation.